Trial
NCT02749292
Maintenance of ANCA Vasculitis Remission by Intermittent Rituximab Dosing
Phase IVTERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Massachusetts General Hospital
Collaborators
—
Condition
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Intervention
Rituximab
Why stopped
Due to the coronavirus disease 2019 (COVID-19) pandemic and the deleterious impact of rituximab on vaccination efficacy, the trial was concluded before reaching the target enrollment of 200.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-07-27